Publications by authors named "Alfonso Fernandez-Ramirez"

Background: Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals achieves a sustained virologic response rate higher than 95%. However, virologic failure remains a clinical challenge, and data on retreatment are limited, especially in special populations such as liver transplant (LT) recipients.

Objectives: This study evaluated the sofosbuvir plus glecaprevir-pibrentasvir (GLE/PIB) regimen in LT recipients who had failed to a nonstructural protein 5A (NS5A) inhibitor-based regimen.

View Article and Find Full Text PDF

Background And Aims: Metabolic-associated fatty liver disease (MAFLD) is a leading cause of chronic liver disease. Nowadays, the prevalence of MAFLD in Mexico is unknown with no screening point-of-care tools. We aimed to estimate the prevalence of MAFLD in Mexico and to develop a score for MAFLD screening.

View Article and Find Full Text PDF

Background: Clostridium difficile infection (CDI) is a leading cause of healthcare-associated diarrhea worldwide. Patients with chronic kidney disease (CKD) are especially vulnerable, as they are exposed to CDI risk factors including frequent antibiotics.

Materials And Methods: In order to identify the risk factors for CDI in CKD patients, a 33-month long case-control study was carried out at a tertiary-care hospital in Mexico.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Alfonso Fernandez-Ramirez"

  • - Alfonso Fernandez-Ramirez's research focuses on chronic liver diseases, particularly the treatment of hepatitis C post-liver transplantation, and the prevalence of metabolic-associated fatty liver disease (MAFLD) in Mexico.
  • - His recent study demonstrated the efficacy of a sofosbuvir plus glecaprevir-pibrentasvir regimen in liver transplant recipients who previously experienced virologic failure, highlighting the need for tailored treatment strategies in special populations.
  • - Additionally, he has developed a screening tool called the MAFLD-S Score to estimate and identify metabolic-associated fatty liver disease prevalence in Mexico, addressing a significant gap in timely diagnosis and management of the condition.